Login to Your Account

Data not questioned, albeit early

Third degree: Nektar, BMS pair graduates with honors across several tumor types

By Randy Osborne
Staff Writer

Tuesday, November 14, 2017

Nektar Therapeutics Inc.'s vice president of clinical development, Mary Tagliaferri, told BioWorld that the compelling objective response rate and impressive disease control rate (DCR) with NKTR-214 when paired with Opdivo (nivolumab) from Bristol-Myers Squibb Co. (BMS) in cancer – along with a clean safety profile and an "antibody-like dosing regimen" once every three weeks – likely put the program in line for accelerated approval.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription